JP7250312B2 - 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 - Google Patents

筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 Download PDF

Info

Publication number
JP7250312B2
JP7250312B2 JP2018549902A JP2018549902A JP7250312B2 JP 7250312 B2 JP7250312 B2 JP 7250312B2 JP 2018549902 A JP2018549902 A JP 2018549902A JP 2018549902 A JP2018549902 A JP 2018549902A JP 7250312 B2 JP7250312 B2 JP 7250312B2
Authority
JP
Japan
Prior art keywords
als
macitinib
alsfrs
patients
aggressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018549902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515884A5 (enExample
JP2019515884A (ja
Inventor
マウジー，アラン
キネット，ジーン‐ピエール
マンスフィールド，コリン
Original Assignee
エービー サイエンス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エービー サイエンス filed Critical エービー サイエンス
Publication of JP2019515884A publication Critical patent/JP2019515884A/ja
Publication of JP2019515884A5 publication Critical patent/JP2019515884A5/ja
Priority to JP2021204244A priority Critical patent/JP2022037132A/ja
Application granted granted Critical
Publication of JP7250312B2 publication Critical patent/JP7250312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018549902A 2016-03-25 2017-03-24 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 Active JP7250312B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021204244A JP2022037132A (ja) 2016-03-25 2021-12-16 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16162490.3 2016-03-25
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021204244A Division JP2022037132A (ja) 2016-03-25 2021-12-16 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用

Publications (3)

Publication Number Publication Date
JP2019515884A JP2019515884A (ja) 2019-06-13
JP2019515884A5 JP2019515884A5 (enExample) 2020-03-12
JP7250312B2 true JP7250312B2 (ja) 2023-04-03

Family

ID=55637258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018549902A Active JP7250312B2 (ja) 2016-03-25 2017-03-24 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用
JP2021204244A Pending JP2022037132A (ja) 2016-03-25 2021-12-16 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021204244A Pending JP2022037132A (ja) 2016-03-25 2021-12-16 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用

Country Status (20)

Country Link
US (1) US10092564B2 (enExample)
EP (1) EP3240538B1 (enExample)
JP (2) JP7250312B2 (enExample)
KR (1) KR102293847B1 (enExample)
CN (1) CN108883108B (enExample)
AU (1) AU2017236177B2 (enExample)
BR (1) BR112018069515A2 (enExample)
CA (1) CA3018635C (enExample)
DK (1) DK3240538T3 (enExample)
EA (1) EA038531B1 (enExample)
ES (1) ES2899929T3 (enExample)
HU (1) HUE057398T2 (enExample)
IL (1) IL261856B (enExample)
MX (1) MX390495B (enExample)
NZ (1) NZ745778A (enExample)
PL (1) PL3240538T3 (enExample)
PT (1) PT3240538T (enExample)
SG (1) SG11201808106YA (enExample)
SI (1) SI3240538T1 (enExample)
WO (1) WO2017162884A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN116889562A (zh) * 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
CN109073634B (zh) 2016-11-25 2022-07-08 基诺富公司 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
CN110475555A (zh) * 2017-03-28 2019-11-19 诺华股份有限公司 治疗多发性硬化的新方法
MX2019014343A (es) * 2017-05-30 2020-08-03 Deciphera Pharmaceuticals Inc Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-n aftiridin-3-il]-2-fluorofenil]-3-fenilurea y analogos para el tratamiento de canceres asociados con anomalias geneticas en el receptor alfa del factor de crecimiento derivado de plaquetas.
EP3762013A4 (en) * 2018-03-05 2022-05-11 The Schepens Eye Research Institute, Inc. THERAPY FOR GLAUCOMA AND OPTICAL NEUROPATHY BY TARGETING COLONY-STIMULATING FACTORS
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation POWDERED FORMULATIONS OF CROMOLYN SODIUM AND ALPHA-LACTOSE
KR20210113610A (ko) 2018-12-10 2021-09-16 더 제너럴 하스피탈 코포레이션 크로몰린 에스테르 및 이의 용도
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途
SMT202400484T1 (it) * 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
SI2118099T1 (sl) 2007-02-13 2011-11-30 Ab Science Postopek za sintezo 2-aminotiazolnih spojin kot kinaznih inhibitorjev
TW201204360A (en) 2010-04-20 2012-02-01 Ab Science Treatment of multiple sclerosis with MASITINIB
US10272082B2 (en) 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
AU2013326463B2 (en) * 2012-10-04 2018-01-18 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
JP6553589B2 (ja) * 2013-03-15 2019-07-31 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ピリミド−ジアゼピノン化合物および障害の治療方法
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃｌｉｎｉｃａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ，２０１５，Ｖｏｌ．３７，Ｎｏ．３，ｐ６６８－６８０
Ｆｒｏｎｔｉｅｒｓ ｉｎ Ａｇｉｎｇ Ｎｅｕｒｏｓｃｉｅｎｃｅ，２０１７．０３．２２，Ｖｏｌ．９，Ａｒｔｉｃｌｅ ６８，ｐ１－１１
Ｈｉｓｔｏｒｙ ｏｆ Ｃｈａｎｇｅｓ ｆｏｒ Ｓｔｕｄｙ： ＮＣＴ０２５８８６７７［オンライン］，２０１５．１０．２７［検索日：２０２０．０１．２０］，インターネット，＜ＵＲＬ：ｈｔｔｐｓ：／／ｃｌｉｎｉｃａｌｔｒｉａｌｓ．ｇｏｖ／ｃｔ２／ｈｉｓｔｏｒｙ／ＮＣＴ０２５８８６７７？Ａ＝１＆Ｂ＝１＆Ｃ＝ｍｅｒｇｅｄ＃ＳｔｕｄｙＰａｇｅＴｏｐ＞

Also Published As

Publication number Publication date
KR20180125966A (ko) 2018-11-26
ES2899929T3 (es) 2022-03-15
CN108883108B (zh) 2021-08-06
DK3240538T3 (da) 2021-12-06
NZ745778A (en) 2022-07-01
KR102293847B1 (ko) 2021-08-26
IL261856A (en) 2018-10-31
EA201800499A1 (ru) 2019-03-29
PL3240538T3 (pl) 2022-01-31
MX2018011349A (es) 2019-02-07
US10092564B2 (en) 2018-10-09
US20180117037A1 (en) 2018-05-03
MX390495B (es) 2025-03-20
SI3240538T1 (sl) 2022-02-28
JP2022037132A (ja) 2022-03-08
AU2017236177B2 (en) 2022-03-31
IL261856B (en) 2022-04-01
EP3240538A1 (en) 2017-11-08
EP3240538B1 (en) 2021-09-29
CA3018635C (en) 2023-09-26
PT3240538T (pt) 2021-12-07
BR112018069515A2 (pt) 2019-04-16
AU2017236177A1 (en) 2018-09-20
WO2017162884A1 (en) 2017-09-28
HUE057398T2 (hu) 2022-05-28
EA038531B1 (ru) 2021-09-10
CA3018635A1 (en) 2017-09-28
CN108883108A (zh) 2018-11-23
JP2019515884A (ja) 2019-06-13
SG11201808106YA (en) 2018-10-30

Similar Documents

Publication Publication Date Title
JP7250312B2 (ja) 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用
KR101571163B1 (ko) 멜라토닌 효능제 치료
US9078894B2 (en) Treatment of severe persistant asthma with masitinib
ES2824552T3 (es) Método de tratamiento con tradipitant
US20140147415A1 (en) Treatment of mastocytosis with masitinib
CN106714819A (zh) 治疗普拉德‑威利综合征的方法
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
US20160263110A1 (en) Use of masitinib for treatment of amyotrophic lateral sclerosis
US7888341B2 (en) Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
HK1261581B (zh) 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途
HK1261581A1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
CN115038446A (zh) 马赛替尼治疗嗜酸性粒细胞性哮喘的用途
US20130072474A1 (en) Treatment of dementia of alzheimer's type with masitinib
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
JP6243850B2 (ja) 抗がん剤による末梢神経障害の予防、治療、または軽減剤
JP2019517516A (ja) Ｓｍａの新規な処置
WO2016071511A1 (en) Treatment of mast cell activation syndrome (mcas) with masitinib
WO2013168315A1 (ja) 認知症及び行動心理学的症候の治療又は予防剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210817

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211216

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220104

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220203

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221004

C27C Written answer of applicant after an oral proceeding

Free format text: JAPANESE INTERMEDIATE CODE: C2721

Effective date: 20221004

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230124

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230221

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230314

R150 Certificate of patent or registration of utility model

Ref document number: 7250312

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150